Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations

被引:79
|
作者
Guchardi, R. [1 ]
Frei, M. [1 ]
John, E. [1 ]
Kaerger, J. S. [1 ]
机构
[1] Novartis Pharma AG, Inhalat Dev & Technol, CH-4002 Basel, Switzerland
关键词
formoterol; DPI; inhalation; lactose; magnesium stearate;
D O I
10.1016/j.ijpharm.2007.06.041
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The behaviour of dry powder blends for inhalation, depending on the amount of fine lactose particles smaller than 10 mu m and the presence of magnesium stearate (MgSt), was studied in this work. A laser light diffraction method was developed to determine accurately size and volume fraction of these fine lactose particles in coarse carrier lactose (x(50) similar to 220 mu m). A linear relationship between measured volume fraction undersize at 10 mu m Q(3)(10 mu m) and added fine lactose could be established. Aerodynamic particle size distribution analysis of lactose showed that the fine lactose was attached to the coarse particles. In the presence of MgSt this interaction was increased. Consequently, the number of free active sites on the carrier surface was reduced and the investigated drug (formoterol fumarate dihydrate) was more effectively delivered. Addition of fine lactose and MgSt improved the aerodynamic performance the drug, as determined by resulting fine particle fraction, by 3% (for each 1% of added fine lactose) and 10%, respectively. Stability tests indicated that added MgSt was the most relevant of the studied parameter to achieve a stable aerodynamic performance. Its ability to protect the moisture uptake into the system was considered as rational for this effect. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [21] Dry powder inhaler device influence on carrier particle performance
    Donovan, Martin J.
    Kim, Sin Hyen
    Raman, Venkatramanan
    Smyth, Hugh D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (03) : 1097 - 1107
  • [22] The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations
    Price, R
    Young, PM
    Edge, S
    Staniforth, JN
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 246 (1-2) : 47 - 59
  • [23] Levofloxacin dry powder inhaler for high dose delivery
    Ceschan, Nazareth Eliana
    Bucala, Veronica
    Ramirez-Rigo, M. Veronica
    POWDER TECHNOLOGY, 2024, 432
  • [24] Airmax™A Multi-Dose Dry Powder Inhaler
    Gillian M. Keating
    Diana Faulds
    Drugs, 2002, 62 : 1887 - 1895
  • [25] Defining the Critical Material Attributes of Lactose Monohydrate in Carrier Based Dry Powder Inhaler Formulations Using Artificial Neural Networks
    Hanne Kinnunen
    Gerald Hebbink
    Harry Peters
    Jagdeep Shur
    Robert Price
    AAPS PharmSciTech, 2014, 15 : 1009 - 1020
  • [26] Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate
    Michael Lau
    Paul M. Young
    Daniela Traini
    AAPS PharmSciTech, 2017, 18 : 2248 - 2259
  • [27] Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate
    Lau, Michael
    Young, Paul M.
    Traini, Daniela
    AAPS PHARMSCITECH, 2017, 18 (06): : 2248 - 2259
  • [28] Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations
    Le, V. N. P.
    Robins, E.
    Flament, M. P.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2012, 80 (03) : 596 - 603
  • [29] Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
    Rashid, Md Abdur
    Muneer, Saiqa
    Wang, Tony
    Alhamhoom, Yahya
    Rintoul, Llew
    Izake, Emad L.
    Islam, Nazrul
    PLOS ONE, 2021, 16 (04):
  • [30] Improving Dry Powder Inhaler Performance by Surface Roughening of Lactose Carrier Particles
    Tan, Bernice Mei Jin
    Chan, Lai Wah
    Heng, Paul Wan Sia
    PHARMACEUTICAL RESEARCH, 2016, 33 (08) : 1923 - 1935